Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06472206 · ClinicalTrials.gov registry record · NA

Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

A NA study of HIV/AIDS, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
420
Enrollment target
5
Study locations

NCT06472206: Recruiting NA study of HIV/AIDS, sponsored by Columbia University.

NCT06472206 is a NA study of HIV/AIDS that is actively recruiting participants, run by Columbia University. The registered enrollment target is 420 participants, below the 33,174-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06472206, a NA study of HIV/AIDS, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
420 participants
Enrollment target
5
Study locations

Study Summary

Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face challenges in accessing healthcare services. In response, a team of experienced researchers has developed and tested the Community Health Workers And MHealth to ImProve Viral Suppression (CHAMPS) intervention. This intervention uses mobile health (mHealth) technology and a team of community health workers (CHW) to design an intervention to improve ART adherence and VS. The CHAMPS+ intervention adds a CHW delivered supportive risk reduction counseling during periods of non-suppression to prevent HIV transmission. The study will engage the participants by developing culturally relevant materials and retention strategies, evaluating the clinical effectiveness and sustainability of the intervention in Deep South settings, and assessing regionalized implementation factors. Ultimately, the study will test the effectiveness of CHAMPS+ on ART adherence and viral load suppression for PWH in Alabama, Louisiana, and Mississippi.

Primary Outcome

Using blood samples obtained during standard of care visits, viral load levels will be used to asses ART adherence.

Conditions Studied

Interventions

  • DEVICE CleverCap
  • BEHAVIORAL CHW Sessions

Study Locations (5)

Alabama

  • Health Services Center, Inc. - Hobson City
  • Unity Wellness Center - Opelika

Louisiana

  • Louisiana State University Health Sciences Center in New Orleans - New Orleans
  • Tulane University - New Orleans

Mississippi

  • University of Mississippi Medical Center - Jackson

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2024-09-23
Est. Completion 2027-12-22
Phase NA
Columbia University

958 total trials

What NCT06472206 shows while recruiting

NCT06472206 is an interventional study that assigns participants to a tested intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap, below the 33,174-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower).

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 2 interventions - of which CleverCap is the first listed.

NCT06472206 lists 5 locations in 3 states (Alabama, Louisiana, Mississippi).

Frequently Asked Questions

What is clinical trial NCT06472206 about?

NCT06472206 is a clinical study titled "Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)". Although global efforts have been made to end the HIV epidemic, there are still some gaps in HIV testing, antiretroviral therapy (ART) adherence, and viral suppression (VS) among people with HIV (PWH). These gaps are particularly prominent in the Deep South of the United States (US), where PWH face ...

What is the current status of trial NCT06472206?

This trial is currently recruiting. It is a NA study. The enrollment target is 420 participants. The study started on 2024-09-23. Estimated completion is 2027-12-22.

What conditions does trial NCT06472206 study?

This clinical trial studies the following conditions: HIV/AIDS.

What interventions are being tested in trial NCT06472206?

The interventions under investigation include: CleverCap (DEVICE), CHW Sessions (BEHAVIORAL).

Who is sponsoring clinical trial NCT06472206?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06472206 being conducted?

This trial has 5 study locations across Alabama, Louisiana, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06472206's enrollment target sits among peer trials

420 13th of 61 higher than 49 of 61 other HIV/AIDS trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01790152 · 420 participants

    Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • NCT02701244 · 420 participants

    A Registry Study of Breast Microseed Treatment

  • NCT02966665 · 420 participants · Phase 1

    : Vascular Function in Health and Disease

  • NCT04149743 · 420 participants · NA

    HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06472206, the US trial registry maintained by the National Library of Medicine. NCT06472206 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.